NeOnc Technologies Holdings, Inc. (NTHI) Stock Price & Analysis

NeOnc Technologies Holdings, Inc. (NTHI) closed at USD 2.75 on Thursday, October 15, 2026, up 3.38% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 2.66; the Oct 15, 2026 session ranged USD 2.67–2.8 on volume of 106,950 shares. Market capitalization is $79.21M, with a 52-week range of USD 2.5–12 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.

Also available as compact Markdown for AI agents: nexqual.com/NTHI.md

Key facts (NTHI)

Analysts (NTHI)

Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 17 (low 13, high 20).

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-09-24Roth CapitalInitiatedBuy$20
2026-09-08BTIGReiteratedBuy$15

Total return (dividends reinvested) (NTHI)

1Y (from 2025-10-16)5Y (from 2025-03-24)
Total return-73.8%-83.4%
S&P 500 (SPY)+18.1%+85.1%
Per year-73.9%-68.3%
Volatility (annualized)111.3%119.9%
Max drawdown-78.6% (Nov 2025→Oct 2026)-83.4% (Mar 2025→Oct 2026)

Key Statistics (as of October 16, 2026 at 05:20 UTC)

PriceUSD 2.75
Change▲ 3.38% (up)
Previous CloseUSD 2.66
OpenUSD 2.79
Day RangeUSD 2.67 – 2.8
52-Week RangeUSD 2.5 – 12
Volume106,950 shares
Market Cap$79.21M
ExchangeNGM

Technical Analysis (NTHI)

Nexqual's technical model rates NTHI "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.

Overall SignalSTRONG SELL
RSI (14)37.12 (neutral)
vs SMA50Below (USD 3.73)
MACD-0.31 (negative)

Analyst Ratings (NTHI)

Wall Street analysts rate NTHI "Buy" based on 4 analysts, with a mean price target of USD 17 (range USD 13–20), per Nexqual as of October 16, 2026 at 05:20 UTC.

Consensus RatingBuy
Analyst Count4
Mean TargetUSD 17
High TargetUSD 20
Low TargetUSD 13
Buy / Hold / Sell4 / 0 / 0

Earnings (NTHI)

Next Earnings Date2026-11-12
EPS EstimateUSD -0.27
Revenue Estimate$0

Recent Earnings History

QuarterActual vs Estimate
2026-06-30USD -0.58 vs est -0.17 ▼ miss
2025-12-31USD -0.35 vs est -0.37 ▲ beat

Source: Nexqual, October 16, 2026 at 05:20 UTC.

Financials & Fundamentals (NTHI)

Total Revenue$39,990
Gross Margin+100.00%
Operating Margin-104418.90%
Profit Margin+0.00%
Current Ratio0.18
Total Cash$1.97M
Total Debt$328,217

Source: Nexqual, October 16, 2026 at 05:20 UTC.

Financial Health Score (NTHI)

Nexqual rates NeOnc Technologies Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.

GrowthMixed — No data
ProfitabilityCritical — Heavily loss-making — early-stage company
Balance SheetMixed — $2M cash, no debt
Cash FlowWeak — Operating cash flow -$21M (TTM)
EfficiencyMixed — No data

Ownership (NTHI)

Insider Ownership+49.77%
Institutional Ownership+10.98%
Shares Outstanding28.81M
Float8.10M
Short % of Float+5.52%

Source: Nexqual, October 16, 2026 at 05:20 UTC.

Leadership (NTHI)

NeOnc Technologies Holdings, Inc. is led by Amir Farrokh Heshmatpour (age 58), President, CEO, Executive Chairman & Secretary, per Nexqual as of October 16, 2026 at 05:20 UTC.

President, CEO, Executive Chairman & SecretaryAmir Farrokh Heshmatpour (age 58)
Founder, Chief Medical Officer, Chief Scientific Officer & Vice ChairmanThomas C. Chen (age 60)
Chief Financial OfficerKeithly A. Garnett (age 50)

Major Backers & Investors (NTHI)

Notable institutional backers of NeOnc Technologies Holdings, Inc. include Cinctive Capital Management LP, Bank of America Corporation, Westmount Partners, LLC , according to Nexqual as of October 16, 2026 at 05:20 UTC.

Active Investors

InvestorStake
Cinctive Capital Management LP6.14%
Bank of America Corporation0.86%
Westmount Partners, LLC 0.75%
Fidelity0.58%
Global Retirement Partners, LLC0.11%

Index Funds (Passive)

FundStake
Vanguard Group4.2%
BlackRock0.82%
Geode Capital0.63%
State Street0.16%
Northern Trust0.14%

Source: Nexqual, October 16, 2026 at 05:20 UTC.

Peers & Related Stocks

SymbolNamePriceChange
RYTMRhythm Pharmaceuticals, Inc.USD 87.97▲ 1.57%
BLTEBelite Bio, IncUSD 152.62▲ 0.49%
IOVAIovance Biotherapeutics, Inc.USD 14.72▲ 1.52%
PRAXPraxis Precision Medicines, IncUSD 248.24▲ 2.01%
IONSIonis Pharmaceuticals, Inc.USD 44.12▲ 4.11%
SYRESpyre Therapeutics, Inc.USD 80.1▼ 0.44%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt